Skip to main content

Table 1 Ex vivo susceptibilities of 215 African Plasmodium falciparum isolates to chloroquine (CQ), quinine (QN), monodesethylamodiaquine (DQ), mefloquine (MQ), lumefantrine (LMF), piperaquine (PPQ), pyronaridine (PND), dihydroartemisinin (DHA), artesunate (AS) and doxycycline (DOX) according to the D113N mutation in the RING E3 ubiquitin protein ligase (PF3D7_0627300) gene

From: The D113N mutation in the RING E3 ubiquitin protein ligase gene is not associated with ex vivo susceptibility to common anti-malarial drugs in African Plasmodium falciparum isolates

Drug Wild-type D113 (31.6%) Mutated 113N (68.4%) p valuec
Mean IC a50 Min and maxb Mean IC50 Min and maxb
CQ 75.5 [6.3–791.6] 75.1 [11.7–615.9] 0.933
QN 128.2 [5.3–631] 124.8 [9.5–690.1] 0.824
DQ 30.3 [1.9–251.5] 30.4 [6.3–196.4] 0.830
MQ 32.9 [5.5–173.4] 40.2 [2.4–172.6] 0.225
LMF 1.33 [0.4–15.1] 1.35 [0.33–16.7] 0.532
PPQ 31.9 [6.8–128.7] 34.0 [7.5–127.5] 0.398
PND 17.1 [1.67–89.2] 15.7 [0.8–123.0] 0.896
DHA 4.02 [0.09–21.1] 3.90 [0.2–28.1] 0.646
ASU 3.64 [0.21–23.6] 3.57 [0.1–21.2] 0.851
DOX 16.8 [0.46–51.1] 16.4 [0.79–49.9] 0.463
  1. aGeometric mean inhibitory concentration 50%
  2. bMinimum and maximum value for each drug
  3. cp values were determined by the Student t test test
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us